The aim of this study was to determine whether quantitative PET parameters on baseline
68Ga-DOTATATE PET/CT and interim PET (iPET) performed before the second cycle of …

We aimed to evaluate 68Ga-DOTATATE PET/CT for the early prediction of time to
progression and clinical outcome after a first cycle of peptide receptor radionuclide treatment …

Purpose [177 Lu] DOTATATE prolongs progression free survival (PFS) in metastatic
neuroendocrine tumours (NETs). However, objective response rate is low. This, coupled …

This study aimed to assess the clinical impact of 68Ga-DOTATATE and 18F-FDG with
respect to the management plan and to evaluate the prognostic value of both tracers …

Purpose The aim of the study was to compare sequential 177 Lu-DOTA-TATE planar scans
(177 Lu-DOTA-TATE) in patients with metastasized neuroendocrine tumours (NET) acquired …

Radiolabeled somatostatin analogs represent valuable tools for both in vivo diagnosis and
therapy of neuroendocrine tumors (NETs) because of the frequent tumoral overexpression of …

Purpose To determine the value of 68 Ga-DOTA-TOC and 18 F-FDG PET/CT for initial and
follow-up evaluation of patients with neuroendocrine tumour (NET) treated with peptide …

We performed post hoc analyses on the utility of pretherapeutic and early interim 68Ga-
DOTATOC PET tumor uptake and volumetric parameters and a recently proposed …

Purpose The prognostic value of FDG PET for neuroendocrine tumours (NETs) has been
reported. In this study we evaluated the role of FDG PET in predicting response and …

The objective of this retrospective study was to determine the role of 18F-FDG PET/CT in a
large cohort of 495 patients with metastatic neuroendocrine neoplasms (NENs) who were …